Skip to main content

Incyte Demands Cake, Bite

NEW YORK, Dec. 16 - Incyte Genomics will change its name next year to Incyte Corporation.

 

The company, which changed its name to Incyte Genomics from Incyte Pharmaceuticals two years ago, said its latest re-christening is designed to reflect a "broader mission" as a company devoted to discovering drugs and selling discovery tools.

 

"This decision was driven by the desire to unify our genomic and proteomic information business, intellectual property and rapidly growing drug discovery organization under the Incyte name," CEO Paul Friedman said without irony. "We believe the name change will help position the company better among our customers, collaborators, stockholders and employees as an emerging drug discovery company."

 

Incyte said it also will "launch a new graphic look" and web site next year "to reflect the new corporate identity."

 

The name change is the latest step in Incyte's slow metamorphosis into a drug company--in this case, a drug company that also happens to sell tools.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.